Abbott Laboratories Hits New 52-Week Low at USD 91.60

Abbott Laboratories has reached a new 52-week low, trading at USD 91.60 on April 22, 2026. This marks a significant decline for the company, which has seen its stock price decrease by 14.69% over the past year, contrasting sharply with the S&P 500's performance of 34.99% during the same period. As a large-cap player in the Pharmaceuticals & Biotechnology industry, Abbott Laboratories boasts a market capitalization of USD 214,677 million. The company maintains a P/E ratio of 32.00, indicating its valuation relative to earnings. Despite the recent stock price decline, Abbott has demonstrated a strong ability to service its debt, evidenced by a low Debt to EBITDA ratio of 0.62 times. The company has also reported positive results for the last three consecutive quarters, with operating cash flow reaching a high of USD 9,037 million. Additionally, Abbott's return on capital employed (ROCE) stands at 13.01%, reflecting its operational efficiency. While the stock is currently trading at a discount compared to its peers, the recent price movement highlights the ongoing volatility in the market.